AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study for Chronic Obstructive Pulmonary Disease

 AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study for Chronic Obstructive Pulmonary Disease

Shots:

  • The P-III ETHOS study involves assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6mcg) vs Bevespi Aerosphere (glycopyrronium/formoterol fumarate 14.4/9.6mcg) and PT009 (budesonide/formoterol fumarate 320/9.6mcg) in symptomatic patients with mod. to sev. COPD
  • The P-III ETHOS study resulted in meeting its 1EPs i/e, reduction in the rate of mod./sev. exacerbations at both standard & half dose of budesonide. The P-III ETHOS study follows KRONOS study which also resulted in reduction of exacerbation in COPD patients
  • Breztri Aerosphere is an approved triple combination therapy in Japan and is under regulatory review in the US, China and EU and Bevespi Aerosphere (FD) is dual bronchodilator, administered in a pressurized metered-dose inhaler utilizing Aerosphere delivery technology

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post